These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 18441690)
1. [International prognostic index in diffuse B large cell lymphosarcoma]. Magomedova AU; Vorob'ev AI Ter Arkh; 2008; 80(3):71-6. PubMed ID: 18441690 [TBL] [Abstract][Full Text] [Related]
5. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255 [TBL] [Abstract][Full Text] [Related]
6. [Nine-year experience in the treatment of patients with diffuse large B-cell lymphosarcoma]. Magomedova AU; Kravchenko SK; Kremenetskaia AM; Zvonkov EA; Bariakh EA; Mangasarova IaK; Kaplanskaia IB; Samoĭlova RS; Vorob'ev IA; Obukhova TN; Karagiulian SR; Shulutko EM; Galstian GM; Mar'in DS; Gabeeva NG; Vorob'ev AI Ter Arkh; 2011; 83(7):5-10. PubMed ID: 21894745 [TBL] [Abstract][Full Text] [Related]
7. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
8. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655 [TBL] [Abstract][Full Text] [Related]
9. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience. Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844 [TBL] [Abstract][Full Text] [Related]
11. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931 [TBL] [Abstract][Full Text] [Related]
12. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371 [TBL] [Abstract][Full Text] [Related]
13. [The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma]. Magomedova AU; Kravchenko SK; Kremenetskaia AM; Zvonkov EE; Bariakh EA; Margolin OV; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Obukhova TN; Moiseeva TN; Zybunova EE; Gemdzhian EG; Vorob'ev AI Ter Arkh; 2006; 78(10):44-7. PubMed ID: 17180937 [TBL] [Abstract][Full Text] [Related]
14. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study. Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398 [TBL] [Abstract][Full Text] [Related]
15. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. Møller MB; Pedersen NT; Christensen BE Am J Hematol; 2003 Oct; 74(2):94-8. PubMed ID: 14508794 [TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226 [TBL] [Abstract][Full Text] [Related]
17. [Primary breast lymphoma--a report of 27 cases with literature review]. Cao YB; Wang SS; Huang HQ; Xu GC; He YJ; Guan ZZ; Lin TY Ai Zheng; 2007 Jan; 26(1):84-9. PubMed ID: 17222374 [TBL] [Abstract][Full Text] [Related]
18. [First experience of using modified program NHL-BFM-90 for the treatment of primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with poor-prognosis]. Morozova AK; Zvonkov EE; Kremenetskaia AM; Magomedova AU; Obukhova TN; Mamonov VE; Bariakh EA; Gubkin AV; Lukina AI; Iliushkina EA; Fink OS; Perestoronina TN; Kravchenko SK Ter Arkh; 2009; 81(7):61-5. PubMed ID: 19708576 [TBL] [Abstract][Full Text] [Related]
19. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660 [TBL] [Abstract][Full Text] [Related]
20. Prognosis of localized diffuse large B-cell lymphoma in younger patients. Møller MB; Christensen BE; Pedersen NT Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]